Compare EMF & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EMF | BNR |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.7M | 252.7M |
| IPO Year | N/A | 2019 |
| Metric | EMF | BNR |
|---|---|---|
| Price | $19.93 | $20.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 42.2K | 27.4K |
| Earning Date | 01-01-0001 | 06-05-2026 |
| Dividend Yield | ★ 6.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.58 | $2.18 |
| 52 Week High | $21.20 | $41.72 |
| Indicator | EMF | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 64.16 | 51.77 |
| Support Level | $16.24 | $19.72 |
| Resistance Level | $20.44 | $23.19 |
| Average True Range (ATR) | 0.43 | 1.44 |
| MACD | 0.18 | 0.55 |
| Stochastic Oscillator | 91.97 | 67.75 |
Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.